FDA Approves GSK ’s Benlysta as the First Medicine for Adult Patients with Active Lupus Nephritis in the US

17 December 2020 --  GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news